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Circulating CD89 and 
IgA nephropathy
The type I receptor glycoprotein FcαRI/
CD89 is expressed on myeloid cells, but 
there is also a soluble form of the protein 
(sCD89) that circulates in plasma and 
tightly binds to immunoglobulin A (IgA). 
The sCD89-IgA complex circulates at 
relatively high concentrations, and it was 
previously proposed that sCD89 might 
contribute to the formation of polymeric 
serum IgA. FcαRI/CD89 is encoded by 
the FCAR gene. Previous studies sug-
gested an association of variations in this 
gene with IgA nephropathy (IgAN), but 
it is unclear whether CD89 contributes 
to IgAN pathogenesis or its phenotype. 
However, previous attempts to quantify 
circulating sCD89 had failed, probably 
because the sCD89 molecule is tightly 
bound to IgA and within the CD89-IgA 
complexes only a minor portion of the 
sCD89 molecule is exposed for antibody 
recognition. To examine whether plasma 
levels of sCD89 are related to IgAN 
susceptibility or disease progression, 
Vuong et al. developed a new assay and 
examined 177 patients with IgAN, 115 
healthy control subjects, and 42 patients 
with other renal diseases. They found no 
significant difference between the sCD89 
levels in the entire group of IgAN patients 
as compared with the healthy control 
group or the group of patients with other 
renal diseases. To investigate a possible 
association between sCD89 levels and 
disease progression, the authors analyzed 
data from 5–15 years of follow-up of 
patients with IgAN, grouping the patients 
into those whose renal disease progressed 
and those who maintained renal func-
tion. This analysis revealed that patients 
without disease progression had high and 
stable levels of sCD89 whereas patients 
with IgAN that progressed had stable but 
low levels of sCD89. The difference was 
not found in patients with other forms 
of renal function. This preliminary study 
TLR4 and anti-MPO 
glomerulonephritis
Anti-myeloperoxidase (anti-MPO) 
antibodies are a cause of crescentic 
glomerulonephritis and pulmonary 
hemorrhage. It was previously found 
that the disease does not occur in the 
absence of neutrophils and that its injury 
is enhanced by lipopolysaccharide 
(LPS). Summers et al. used purified 
LPS (a Toll-like receptor 4 (TLR4) 
ligand) and anti-MPO antibodies to 
synergistically increase kidney and lung 
neutro phil recruitment and functional 
injury. These effects were abrogated in 
TLR4-deficient mice. After stimulation, 
glomerular cells expressed TLR4, 
particularly in the endothelium. In 
addition, the enhanced glomerular 
neutrophil recruitment correlated with 
increased kidney mRNA expression of 
CXCL1 and CXCL2 (the homologs of 
human CXCL8), and their inhibition 
decreased neutrophil recruitment. 
Experiments in bone marrow chimeric 
mice showed that TLR4 in both the 
bone marrow and renal cells is required 
for maximal effect. These studies thus 
show a role for TLR4 in the bone mar-
row and in glomerular endothelium 
in the recruitment of neutrophils and 
the resulting renal injury of exper-
imental anti-MPO glomeru lonephritis. 
See page 1263.
therefore suggests a genetic component in 
the regulation of sCD89 production that 
is associated with the severity of IgAN 
progression. See page 1281.
Klotho is renoprotective 
in acute kidney injury
Klotho is a protein with multiple func-
tions that is highly expressed in the kidney 
and is present in blood and urine. Hu et 
al. examined the potential effect of acute 
kidney injury (AKI) on renal Klotho. They 
report that renal ischemia–reperfusion in 
rodents reduced Klotho levels in the kid-
neys, as well as in urine and blood, and 
that the levels normalized upon recovery. 
Moreover, patients with AKI had marked 
reductions in urinary Klotho. To examine 
whether Klotho may play a pathogenic 
role, they induced ischemia–reperfusion 
in kidneys of mice with different endog-
enous Klotho levels ranging from hetero-
zygous Klotho haploinsufficient, to wild 
type, to transgenic mice overexpressing 
the protein. The haploinsufficient mice 
had worse kidney injury than wild-type 
mice, while injury was milder in overex-
pressing transgenic mice. Similarly, rats 
given recombinant Klotho had less kidney 
damage after ischemia–reperfusion. This 
study indicates that AKI is a state of acute 
reversible Klotho deficiency, and that 
low levels of Klotho exacerbate and high 
levels attenuate renal damage. Hence, 
the study suggests potential thera peutic 
effects of Klotho in acute renal failure. 
See page 1240.
